Skip to search formSkip to main contentSkip to account menu

DT(388)IL3 fusion protein

Known as: IL3R-targeting Fusion Protein SL-401, SL-401, DT(388)-IL3 Fusion Protein 
A recombinant protein consisting of human interleukin 3 (IL3) fused to the first 388 amino acids of diphtheria toxin [DT(388)] (DT388IL3) with… 
National Institutes of Health

Related topics

Related topics

4 relations
NCIt Antineoplastic Agent TerminologyPeptide Elongation Factor 2Positive Regulation of ApoptosisTranslational Repression

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm.
2019
2019
Results from ongoing phase 1/2 clinical trial of tagraxofusp (SL-401) in patients with intermediate or high risk relapsed/refractory myelofibrosis.
7058 Background: Patients with myelofibrosis (MF) who fail or are intolerant to JAK inhibitors (JAKi) have no standard treatment… 
Review
2019
Review
2019
Treatment advances in blastic plasmacytoid dendritic cell neoplasm.
NP BPDCN is an aggressive cancer of the blood and bone marrow that presents clinically as a hybrid of lymphoma and leukemia. In… 
2016
2016
Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Lead-in completed, expansion stage ongoing.
7006Background: SL-401 is a targeted therapy directed to the interleukin-3 receptor (CD123), a target overexpressed on BPDCN and… 
2016
2016
Results from Ongoing Phase 1/2 Trial of SL-401 in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Background: The bone marrow microenvironment of many multiple myeloma (MM) patients harbors high quantities of plasmacytoid… 
Review
2015
Review
2015
Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells.
2015
2015
Lead-in Stage Results of a Pivotal Trial of SL-401, an Interleukin-3 Receptor (IL-3R) Targeting Biologic, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) or Acute Myeloid…
Background: SL-401 is a novel biologic delivering a truncated diphtheria toxin, a highly potent protein synthesis inhibitor, to… 
2013
2013
An Update On The Robust Clinical Activity Of SL-401, a Targeted Therapy Directed To The Interleukin-3 Receptor On Cancer Stem Cells and Tumor Bulk, In Patients With Blastic Plasmacytoid Dendritic…
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is an aggressive hematologic malignancy derived from plasmacytoid dendritic… 
2012
2012
SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML
Abstract 3625 Background: SL-401 is a novel biologic targeted therapy, comprised of human IL-3 coupled to a truncated diphtheria… 
2010
2010
Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and…
Abstract 3298 Background and Rationale: SL-401 (DT388IL3) is a novel cancer stem cell (CSC)-directed recombinant biologic agent… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)